Federal program · Explained

Medicare GLP-1 Bridge: $50/Month Explained (2026)

Facts quoted from CMS, dated below · program facts last verified August 15, 2026 · utilization reporting current through September 15, 2026

RangeYourself earns nothing from the Medicare GLP-1 Bridge. There is no affiliate link on this page and nothing here is paid placement; we are explaining a federal program because readers ask about it, not because we are compensated for it.

What the program actually does

CMS describes the Bridge this way: “Eligible Medicare beneficiaries may now get certain GLP-1 medications for $50 per month through the Medicare GLP-1 Bridge, a new Centers for Medicare & Medicaid Services (CMS) initiative designed to expand access to innovative treatments and test the impacts of increased access to GLP-1 drugs for weight management on the Medicare program.” It operates outside your normal Part D benefit rather than inside it, which is why the copay does not move with your deductible phase. CMS states: “no part of the $50 copay would count toward the beneficiary's true out-of-pocket costs (TrOOP) under their Part D plan. In addition, the $50 copay for eligible beneficiaries would remain the same, regardless of the phase of the Part D benefit an eligible beneficiary is in when they fill a prescription for an eligible GLP-1 drugs covered under the Medicare GLP-1 Bridge. Similarly, low-income cost-sharing subsidies would also not apply to any portion of the copay.”

Your own Part D plan does not have to opt in for you to use it: CMS states “Part D sponsors will not carry risk for eligible GLP-1 drugs furnished under the Medicare GLP-1 Bridge, and Part D sponsors do not have to opt in to the Medicare GLP-1 Bridge for eligible beneficiaries to access these drugs beginning July 1, 2026.” A single central processor, not your plan, handles the prior authorization, the claim, and the payment to your pharmacy.

Which drugs, and which forms of them

CMS states: “At this time, for the purposes of the Medicare GLP-1 Bridge, an eligible GLP-1 drug is any of the following products when used to reduce excess body weight and maintain weight reduction: Foundayo®, Wegovy® (injection and tablets), and Zepbound® (KwikPen®).” The Zepbound formulation is narrower than that list implies. CMS states: “The single-dose vial and single-dose pen formulations of Zepbound® will not be available through the Medicare GLP-1 Bridge.” Foundayo, the once-daily pill approved April 1, 2026, is explicitly on the covered list. Lilly’s own LillyDirect Foundayo page states: “If you are an eligible Medicare Part D patient with a Foundayo prescription for weight management, learn more about how to access Foundayo through the Medicare GLP-1 Bridge program,” pointing eligible patients at the Bridge instead of LillyDirect’s own self-pay pricing.

Source: LillyDirect, Foundayo, read 2026-09-15.

Who qualifies, in CMS’s own words

These are quoted regulatory criteria, not RangeYourself’s medical opinion, and they are not a self-assessment. CMS requires a prescriber to submit the request: “For a beneficiary to qualify for the Medicare GLP-1 Bridge, a provider must submit a prior authorization request that attests the beneficiary meets the following criteria:”

The beneficiary is prescribed the requested drug to reduce excess body weight and maintain weight reduction in combination with current and ongoing lifestyle modification including structured nutrition and physical activity consistent with the applicable FDA approved label, AND
The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty-five (≥35) at the time of initiation of GLP-1 therapy, or
The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty (≥30) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: (A) heart failure with preserved ejection fraction, (B) uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with two antihypertensive medications), or (C) chronic kidney disease stage 3a or above, or
The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to twenty-seven (≥27) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: (A) pre-diabetes (as defined by American Diabetes Association guidelines), (B) previous myocardial infarction, (C) previous stroke, or (D) symptomatic peripheral artery disease.

Quoted from CMS, Medicare GLP-1 Bridge FAQs for Part D Plans, read 2026-08-15. Whether you meet them is a clinical judgment for the prescriber who has to attest to it, not something to decide from this page.

Four things that disqualify people who assume they qualify

It is for weight management only. CMS states: “Eligible GLP-1s are only furnished under the Medicare GLP-1 Bridge, with the $50 co-pay, when prescribed for a weight management indication. If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
Diabetes, sleep apnea, and MASH route elsewhere. CMS states: “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. Beneficiaries with these diagnoses are eligible to receive GLP-1s through their Part D plan and therefore are ineligible to receive them through the Medicare GLP-1 Bridge, even if they otherwise meet the Medicare GLP-1 Bridge clinical criteria.”
A GLP-1 already filled through Part D this year. CMS states: “If the beneficiary has previously filled a prescription for a GLP-1 through their Part D plan in 2026, they are not eligible for coverage through Medicare GLP-1 Bridge in 2026, even if that coverage was supplemental coverage of weight management by their Part D plan.”
No stacking coupons on top of it. CMS states: “Coupons and discount programs may not be applied to Medicare GLP-1 Bridge claims.”

How much the program has actually been used

CMS has not published an official enrollment or fill count for the Bridge; NPR reported this explicitly when it asked. What exists instead is what individual pharmacy chains have told reporters. NPR (Sydney Lupkin, August 26, 2026) reported that CVS and Walgreens each said they had filled around 100,000 Bridge prescriptions in the program’s first seven weeks, and that Walmart said Bridge prescriptions had “now been processed at more than 5,000 Walmart and Sam’s Club pharmacies nationwide,” without giving a total count. Becker’s Hospital Review (Elizabeth Casolo, September 14, 2026) reported that both CVS and Walgreens now describe their own totals as “more than 100,000” each, and quoted Walgreens’ chief pharmacy officer Rick Gates saying uptake is “far exceeding” the company’s own volume expectations.

Separately, CMS Administrator Mehmet Oz said in a video posted to X on July 29, 2026 that 250,000 beneficiaries had signed up. NPR notes it is not clear whether those sign-ups all received an approved prior authorization, which is required before a prescription can actually be filled. For scale: Jeremy Shane, a nonresident scholar at the USC Leonard D. Schaeffer Institute for Public Policy & Government Service, told NPR that Medicare had estimated roughly 4 million beneficiaries could be eligible, and that the pharmacy-chain numbers put early participation at somewhere between 5% and 10% of that eligible population within the program’s first weeks. NPR also reported that the nonpartisan research group KFF has estimated the 18-month program could cost the federal government between $1.3 billion and $10 billion depending on how many eligible beneficiaries ultimately participate, against $181 billion in total 2025 Part D drug spending. RangeYourself has not independently read KFF’s own estimate; this figure is reported as NPR described it.

Gates also told Becker’s he expects growth to plateau rather than keep accelerating: some patients will stay on therapy long-term, he said, while others will transition off, producing “a natural run rate” rather than continued rapid growth. He named the open question as what happens to patients’ coverage after the program’s current window ends.

Sources: NPR, August 26, 2026; Becker’s Hospital Review, September 14, 2026, both read 2026-09-15.

The reported friction in getting approved

A $50 headline price is not the same as an easy approval. Dr. Jeffrey Millstein, an internist and regional medical director for primary and specialty care at Penn Medicine, wrote in STAT News (August 11, 2026) that the program “requires extensive documentation, prior authorizations, appeals, and time-consuming navigation of evolving coverage rules,” and that “access depends not only on medical need but also on a practice’s administrative capacity. Beneficiaries who lack the health literacy, time, or resources to navigate the program independently may find themselves effectively excluded.” He added that some practices “may decide that participation in the Bridge program is simply not sustainable.”

That is one physician’s published assessment based on his own practice, not a measured national denial or approval rate; CMS has not published an approval-rate figure for Bridge prior authorizations. Walgreens, for its part, told Becker’s that Bridge’s separation from individual health plans’ own prior- authorization criteria makes the process more direct for the pharmacies and patients it serves. Both things can be true at once: simpler than a typical commercial-plan prior authorization, and still a real administrative burden for a practice or patient navigating it for the first time.

Source: STAT News, First Opinion, August 11, 2026, read 2026-09-15.

What happens when the demonstration ends

CMS states: “The Medicare GLP-1 Bridge will be extended through December 31, 2027, providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allowing CMS to collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D.” BALANCE is the permanent Part D pathway the Bridge was originally meant to lead into. As of this page’s last check, CMS has confirmed BALANCE is not launching in 2027 as planned, and has not announced whether Bridge itself will be extended again, replaced, or allowed to end on schedule. Gates named this directly to Becker’s as “the biggest watch-out”: patients established on a GLP-1 through Bridge who may not have a clear coverage path once the demonstration’s current window closes.

Source: CMS, Medicare GLP-1 Bridge FAQs, read 2026-09-15.

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

Frequently asked questions

What is the Medicare GLP-1 Bridge?

A time-limited CMS demonstration that lets eligible Medicare Part D beneficiaries fill certain GLP-1 drugs for a flat $50 monthly copay. CMS states: "Eligible Medicare beneficiaries may now get certain GLP-1 medications for $50 per month through the Medicare GLP-1 Bridge, a new Centers for Medicare & Medicaid Services (CMS) initiative designed to expand access to innovative treatments and test the impacts of increased access to GLP-1 drugs for weight management on the Medicare program." It runs from July 1, 2026 through December 31, 2027.

Which drugs does the Medicare GLP-1 Bridge cover?

CMS states: "At this time, for the purposes of the Medicare GLP-1 Bridge, an eligible GLP-1 drug is any of the following products when used to reduce excess body weight and maintain weight reduction: Foundayo®, Wegovy® (injection and tablets), and Zepbound® (KwikPen®)." The Zepbound formulation is limited: CMS also states "The single-dose vial and single-dose pen formulations of Zepbound® will not be available through the Medicare GLP-1 Bridge."

Who qualifies for the Medicare GLP-1 Bridge?

A prescriber has to submit a prior authorization attesting the beneficiary meets CMS's clinical criteria (age, BMI, and specific comorbidities), and the prescription has to be for weight management, not for diabetes, sleep apnea, or MASH, which route through Part D instead. See the full criteria and disqualifiers below; whether you meet them is a clinical judgment for your prescriber.

How many people have used the Medicare GLP-1 Bridge?

CMS has not published an official enrollment or fill count. NPR reported 2026-08-26 that CVS and Walgreens each told the network they had filled around 100,000 Bridge prescriptions in the program's first seven weeks; Becker's Hospital Review reported 2026-09-14 that both companies now say "more than 100,000" each. Separately, CMS Administrator Mehmet Oz stated in a July 29, 2026 video that 250,000 beneficiaries had signed up, though it is not confirmed whether all of those sign-ups received an approved prior authorization. These are the numbers that exist; RangeYourself has not estimated a total beyond what these sources report.

Is it hard to actually get approved for the Medicare GLP-1 Bridge?

Some physicians say yes. Dr. Jeffrey Millstein, an internist and regional medical director at Penn Medicine, wrote in STAT News (2026-08-11) that the program "requires extensive documentation, prior authorizations, appeals, and time-consuming navigation of evolving coverage rules," and that "beneficiaries who lack the health literacy, time, or resources to navigate the program independently may find themselves effectively excluded." That is one physician's published assessment, not a measured denial rate; CMS has not published a prior-authorization approval rate for the program.

What happens to the Medicare GLP-1 Bridge after 2027?

Unclear. CMS states: "The Medicare GLP-1 Bridge will be extended through December 31, 2027, providing eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs and allowing CMS to collect additional data on GLP-1 utilization to share with Part D plan sponsors ahead of potential implementation of BALANCE in Part D." BALANCE, the permanent Part D pathway the Bridge was meant to lead into, has not launched as planned. Whether Bridge is extended again, replaced, or ends on schedule has not been announced.

How does the $50 Bridge copay compare to buying a GLP-1 without it?

It is the cheapest published route to any of these drugs that publishes a figure at all: less than a compounded telehealth program's cheapest listed price of $50 a month, and far below Foundayo's or Zepbound's own manufacturer self-pay prices. But it only applies if you are an eligible Medicare Part D beneficiary with an approved prior authorization; it is not a price anyone else can pay. See our full breakdown of <a href="/cheapest-way-to-get-glp1">every route to a GLP-1, priced</a>.

This page is for information, not medical advice, and has not been reviewed by a clinician. Eligibility rules quoted above are CMS’s own published terms as of the dates shown, and they can change; the Bridge program itself is a temporary demonstration, not a permanent benefit. Talk to a licensed provider and to Medicare directly (1-800-MEDICARE or Medicare.gov/glp1bridge) about whether you qualify; no page can tell you that, and no pharmacy or provider can guarantee an approved prior authorization.